SLC6A4 and schizophrenia: Admittedly, SERT expression or indicators of tonic 5-HT release in PCP-Iso remain unexplored, but any serotonergic dysfunction in schizophrenia [92], isolation-reared [93–95] or neonatal NMDA antagonist-treated rats [96, 97] appears far less extensive than that produced by intentional median raphe lesions that abolished 5-HT6 antagonists’ effect on NOD during dissociation of relevant neuroanatomical substrates [98].